MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash acquired in
connection with the merger
$102,113K
Proceeds from issuance of
common stock in private...
$42,000K
Proceeds from issuance of
pre-funded warrants in...
$8,000K
Proceeds from the
issuance of convertible...
$7,500K
Net cash provided by
financing activities
$155,007K
Canceled cashflow
$4,606K
Net increase
(decrease) in cash and cash...
$96,914K
Canceled cashflow
$58,093K
Payment of deferred
transaction costs and...
$2,937K
Payment of issuance
costs
$1,669K
Accrued expenses and
other current...
$2,144K
Stock-based compensation
expense
$1,936K
Prepaid expense and
other current assets
-$1,810K
Non-cash interest
expense (including...
$1,443K
Loss on
extinguishment and on issuance...
-$186K
Non-cash operating lease
expense
-$53K
Depreciation expense
$13K
Maturities of short-term
marketable securities
$15,000K
Net cash used in
operating activities
-$38,370K
Net cash used in
investing activities
-$19,723K
Canceled cashflow
$7,585K
Canceled cashflow
$15,000K
Net loss
-$43,438K
Purchases of short-term
marketable securities
$34,523K
Change in fair value of
derivative liabilities...
$1,229K
Net amortization of
premiums and accretion of...
$399K
Change in fair value of
tranche liability...
$365K
Other non-current
assets
$355K
Accounts payable
-$88K
Operating lease
liabilities
-$81K
Purchase of property and
equipment
$200K
Back
Back
Cash Flow
source: myfinsight.com
Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (KLRS)